title: [Cutaneous reaction after pyrazinamide initiation].
authors: P
authors: P
authors: Mulliez
authors: F-L
authors: FL
authors: Mbassi Fouda
authors: F
authors: F
authors: Roy Saint-Georges
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004338:Drug Combinations; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology*; D004359:Drug Therapy, Combination; D004408:Dysgeusia / Q000139:chemically induced; D005483:Flushing / Q000139:chemically induced; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D017336:Loratadine / Q000627:therapeutic use; D008297:Male; D011537:Pruritus / Q000139:chemically induced / Q000188:drug therapy; D011718:Pyrazinamide / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D012008:Recurrence; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D053802:Tryptases / Q000097:blood; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy; D014664:Vasodilation / Q000187:drug effects
chemical_list: D000995:Antitubercular Agents; D004338:Drug Combinations; D006634:Histamine H1 Antagonists; C087181:isoniazid, pyrazinamide, rifampin drug combination; D011718:Pyrazinamide; D017336:Loratadine; D053802:Tryptases; D007538:Isoniazid; D012293:Rifampin